Evidence map›Paper›PMID 41981213›Full record

ArticleScientific reports2026

Feasibility and utility of a tablet-based digital neurocognitive assessment following radiosurgery for brain metastases.

Eyub Y Akdemir, Joseph DiStefano, Thailin Companioni Reyes, Yazmin Odia, Robert H Press, Matthew D Hall, D Jay Wieczorek, Yongsook C Lee, Ranjini Tolakanahalli, Alonso N Gutierrez and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05504681 (Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05504681 recruitingnot on this map

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

TypeobservationalSponsorBaptist Health South FloridaRan2021 to 2032Enrolled200ConditionsNeurocognitive DisordersArmsObservational study
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eyub Y AkdemirDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Joseph DiStefanoDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Thailin Companioni ReyesDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Yazmin OdiaDepartment of Neuro-Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Robert H PressDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Matthew D HallDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
D Jay WieczorekDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Yongsook C LeeDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Ranjini TolakanahalliDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Alonso N GutierrezDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Michael W McDermottHerbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Minesh P MehtaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA.
Rupesh KotechaDepartment of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, 33176, USA. RupeshK@baptisthealth.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurocognitive decline (NCD) is a significant concern for patients with brain metastases, yet traditional paper-based assessments are often burdensome. This prospective cohort study evaluated the feasibility and outcomes of a tablet-based digital neurocognitive battery in patients with prior stereotactic radiosurgery (SRS). Data were analyzed from an institutional prospective registry (NCT05504681) including 41 adults with prior SRS. Patients were stratified into a high-risk group (undergoing repeat SRS for progression) and a low-risk group (surveillance only). Neurocognitive function was assessed using the “Cognition” tablet-based platform. NCD was defined as significant deterioration in at least 1 test at 3 months using the Reliable Change Index. The median age was 66 years, and 46% of assessments were conducted in Spanish. Learning and memory were the most frequently affected domains (32%). At 3 months, NCD rates were significantly higher in the high-risk cohort (76%) compared to the low-risk cohort (40%; p = 0.019). On multivariable analysis, risk group status was the only independent predictor of NCD (p = 0.030). Patient feedback indicated high satisfaction and usability. Digital neurocognitive assessment is a feasible and sensitive tool for monitoring patients with brain metastases. The platform effectively differentiated between patients undergoing repeat SRS and those under surveillance, underscoring the importance of routine cognitive monitoring.

Indexed as

Brain NeoplasmsComputers, HandheldRadiosurgeryAgedCognitionFeasibility StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsProspective StudiesBrain metastasesDigital neurocognitive toolNeurocognitive assessment

Identifiers

PMID41981213
PMCPMC13237174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.